RT Journal Article
SR Electronic
T1 ADESSO: a rapid, adaptable and sensitive Cas13-based COVID-19 diagnostic platform
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21258371
DO 10.1101/2021.06.17.21258371
A1 Casati, Beatrice
A1 Verdi, Joseph Peter
A1 Hempelmann, Alexander
A1 Kittel, Maximilian
A1 Klaebisch, Andrea Gutierrez
A1 Meister, Bianca
A1 Welker, Sybille
A1 Asthana, Sonal
A1 Boskovic, Pavle
A1 Man, Ka Hou
A1 Schopp, Meike
A1 Ginno, Paul
A1 Radlwimmer, Bernhard
A1 Stebbins, Charles Erec
A1 Miethke, Thomas
A1 Papavasiliou, Fotini Nina
A1 Pecori, Riccardo
YR 2021
UL http://medrxiv.org/content/early/2021/10/06/2021.06.17.21258371.abstract
AB SARS-CoV-2 is the causative agent for a pandemic that has had immense consequences for the health and economic sectors worldwide. While PCR testing and later antigen tests have proven critical for helping to stem the spread of the virus, these methods suffer from general applicability and sensitivity, respectively. Moreover, the emergence of variant strains creates the need for flexibility to correctly and efficiently diagnose the presence of substrains in the population. To address these needs we have developed the diagnostic test ADESSO (Accurate Detection of Evolving SARS-CoV-2 through SHERLOCK Optimization) which employs the Cas13 system to diagnose patients in as little as 1 hour without sophisticated equipment. Using an extensive panel of clinical samples, we demonstrate that ADESSO correctly identifies COVID-19 positive samples at a sensitivity and specificity comparable to RT-qPCR on extracted RNA and higher than antigen tests for unextracted samples. Taken together, ADESSO is a fast, sensitive and cheap method that can be applied in a point of care (POC) setting to diagnose COVID-19 and can be quickly adjusted to detect new variants.Competing Interest StatementThe DKFZ has filed patent applications regarding this diagnostic methodology (EP 20 173 912.5). RP, FNP and BC are inventors on the above-mentioned patent applications.Funding StatementThe work was supported by a grant from the Ministry of Science, Research and the Arts of Baden-Wuerttemberg for COVID-19 research (grant agreement no. Kap. 1499 TG 93 to Dr. Riccardo Pecori, Prof. Dr. Nina Papavasiliou (DKFZ) and Prof. Dr. Thomas Miethke (Medical Faculty of Mannheim))Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee II of the University of Heidelberg (Medical Faculty of Mannheim) ruled the ethics for all the clinical samples used in this study. The committee reviewed and approved the proposal for the collection and use of gargle fluids (ref. 2020-556N). Regarding the use of nose-throat samples, the ethic committee reviewed that proposal and concluded that according to the professional code of conduct for doctors and germans regulations, the evaluation by an ethics committee is unnecessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data will be available after the publication of this article.